Patent Suits Trigger Molecular Diagnostics Business Uncertainty
This article was originally published in The Gray Sheet
Executive Summary
Investment in new molecular diagnostics biomarkers, particularly genetic markers, is suffering due to substantial patent law uncertainties, according to test developers at last week's Biotechnology Industry Organization conference in Chicago